RESUMO
A patient presenting with concomitant epidermal growth factor receptor [EGFR] mutation and anaplastic lymphoma kinase [ALK] translocation is very rare. We report a non-small cell lung cancer [NSCLC] patient with concomitant EGFR [exon 19-del] mutation and ALK rearrangement. The positron emission tomography-computed tomography [PET-CT] scan revealed a highly metabolic mass lesion in the left lower lobe, measured 5.0 cm in the largest dimension in the S6 segment. Transbronchial lung biopsy [TBLB] showed the pathological diagnosis of invasive adenocarcinoma. Thus, the patient underwent left lower lobectomy and hilar-mediastina lymph node dissection [pT2N0M0]. The tumor harbor an ALK [D5F3 +] rearrangement and EGFR [exon 19-del] mutation. The patient initially received four cycles of chemotherapy [pemetrexed and carboplatin], and achieved partial response [PR]
RESUMO
Nedaplatin [NDP] is a second-generation platinum derivative that was developed in Japan. Nowadays, it is being widely used in the management of lung cancer, esophageal cancer, head and neck cancers, especially when cisplatin and carboplatin cannot be tolerated or show drug resistance. To the best of our knowledge, there are few reported cases of NDP-induced bradycardia in the relevant medical literature. The current report presents three patients treated with NDP chemotherapy-induced serious arrhythmias. The three cases developed sinus tachycardia and atrial premature beats, complete left bundle branch block, and bigeminy ventricular premature contraction, in the second, sixth and second cycle, respectively. No one died of cardiac toxicity. These were treated with dexamethasone, 5 mg intravenous injection and diphenhydramine 20 mg, intramuscular injection. The heart rhythm returned to normal in 30 minutes, a day, and four days, respectively